Multiple sclerosis
The guideline here is NICE NG220 (2022, amended 2026), which covers diagnosis, symptom management, relapse and disease-modifying therapy for adults. Diagnosis now follows the 2024 revised McDonald criteria.
Clinical pearls
- Relapse: >24 h, ≥30 days after the last one, no infection or fever. Methylprednisolone 0.5 g oral for 5 days (or 1 g IV for 3–5 days).
- Spasticity: baclofen, then gabapentin. Oscillopsia: gabapentin, then memantine.
- Primary progressive MS: ocrelizumab. Active secondary progressive: siponimod.